

# Azerbaijan

Population 2015

9.8 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.038 (0.035–0.042)	0.39 (0.36–0.43)
Mortality (HIV+TB only)	0.02 (<0.01–0.055)	0.21 (0.03–0.56)
Incidence (includes HIV+TB)	6.8 (5.5–8.1)	69 (57–83)
Incidence (HIV+TB only)	0.11 (0.07–0.16)	1.1 (0.72–1.6)
Incidence (MDR/RR-TB)**	2.5 (2–3)	26 (21–31)

## Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	0.24 (0.098–0.39)	1.9 (1–2.7)	2.1 (1.1–3.1)
Males	0.36 (0.24–0.49)	4.3 (3.3–5.3)	4.7 (3.6–5.8)
Total	0.61 (0.44–0.78)	6.2 (5.4–6.9)	6.8 (5.5–8.1)

## TB case notifications, 2015

Total cases notified	7 501
Total new and relapse	5 456
- % tested with rapid diagnostics at time of diagnosis	43%
- % with known HIV status	128%
- % pulmonary	80%
- % bacteriologically confirmed among pulmonary	60%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	81% (67–98)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.01 (0–0.01)

## TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	112	2%
- on antiretroviral therapy	89	79%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			1 400 (1 100–1 600)
Estimated % of TB cases with MDR/RR-TB	13% (10–16)	29% (23–35)	
% notified tested for rifampicin resistance	32%	68%	3 687
MDR/RR-TB cases tested for resistance to second-line drugs			676
Laboratory-confirmed cases		MDR/RR-TB: 1 171, XDR-TB: 109	
Patients started on treatment ****		MDR/RR-TB: 827, XDR-TB: 95	

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2014	83%	1 623
Previously treated cases registered in 2014	74%	2 374
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013	59%	647
XDR-TB cases started on second-line treatment in 2013	26%	95

## TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	33%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (85–100)

## TB financing, 2016

National TB budget (US\$ millions)

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2015




## Treatment success rate (%)



— New cases  
— Previously treated cases  
— HIV-positive — MDR/RR-TB — XDR-TB

## Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically